Aura Biosciences Stock
Development of drugs by using tumor targeted Pseudovirions
Sign up today and learn more about Aura Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Aura Biosciences Stock
Aura Biosciences, Inc. is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. Aura's NanoSmart drug delivery system aims to solve critical issues in drug delivery by encapsulating therapies within protein nanoparticles engineered for precise targeting, immune system evasion and efficient cellular uptake Aura combines the expertise of leading European and US research institutions with the flexibility and efficiency of a dedicated team of in-house scientists, deal-makers and world class advisors. The company is located in Cambridge, Massachusetts.
Funding History
| September 2010 | $1.4M |
|---|---|
| August 2011 | $3.0M |
| December 2012 | $3.2M |
| January 2014 | $1.3M |
| August 2014 | $4.0M |
| March 2015 | $21.0M |
| September 2016 | $8.0M |
| December 2017 | $30.0M |
| April 2019 | $40.0M |
Management
Senior Vice President of Development
Stephen Monks
Vice President of Clinical Development
Denis O’Shaughnessy
Founder and CEO
Elisabet de los Pinos
Senior Vice President, R&D Operations
Michele Keough
Chief Medical Officer
Cadmus Rich
Chief Financial Officer
Julie Feder
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
